In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMimetic Therapeutics, Inc.

http://www.biomimetics.com

Latest From BioMimetic Therapeutics, Inc.

Stockwatch: The Pandemic – Where Generics Failed To Reign

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

Companies Generic Drugs

First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod

New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.

Approvals Coronavirus COVID-19

Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow

Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.

Generic Drugs Sales & Earnings

Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings

Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.

Commercial Cancer
See All

Company Information

UsernamePublicRestriction

Register